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B cell activating factor of the TNF family (BAFF), also known
as B lymphocyte stimulator, is a ligand required for the genera-
tion andmaintenance of B lymphocytes. In this study, the ability
of differentmonoclonal antibodies to recognize, inhibit, or acti-
vate mouse BAFF was investigated. One of them, a mouse IgG1
named Sandy-2, prevented the binding of BAFF to all of its
receptors, BAFF receptor, transmembrane activator and cal-
cium modulating ligand interactor, and B cell maturation anti-
gen, at a stoichiometric ratio; blocked the activity of mouse
BAFFon a variety of cell-based reporter assays; and antagonized
theprosurvival actionofBAFFonprimarymouseB cells in vitro.
A single administration of Sandy-2 inmice inducedB cell deple-
tion within 2 weeks, down to levels close to those observed in
BAFF-deficient mice. This depletion could then be maintained
with a chronic treatment. Sandy-2 andapreviously described rat
IgG1 antibody, 5A8, also formed a pair suitable for the sensitive
detection of endogenous circulating BAFF by ELISA or using a
homogenous assay. Interestingly, 5A8 and Sandy-5 displayed
activities opposite to that of Sandy-2 by stimulating recombi-
nant BAFF in vitro and endogenous BAFF in vivo. These tools
will prove useful for the detection and functional manipulation
of endogenous mouse BAFF and provide an alternative to the
widely used BAFF receptor-Fc decoy receptor for the specific
depletion of BAFF in mice.
The ligand B cell activating factor of the TNF family (BAFF),4
also known as B lymphocyte stimulator, and its close relative a
proliferation-inducing ligand (APRIL) play important roles in
the generation andmaintenance of B cells (1). BAFF andAPRIL
share two receptors, transmembrane activator and calcium
modulating ligand interactor (TACI) and B cell maturation
antigen (BCMA), whereas BAFF additionally binds to BAFF
receptor (BAFFR; also known as BR3). BAFF acts on BAFFR to
support survival and fitness of transitional andmature B cells in
the periphery, a conclusion supported by the observation that
BAFF-deficient and BAFFR-deficient mice have few mature
peripheral B cells, whereas the reverse is observed in BAFF
transgenic mice (for a review, see Ref. 1). BCMA is expressed
late in the B cell differentiation process (2) and participates in
the maintenance of plasma cells in vivo (3). The function of
TACI appears to be dual: on the one hand, it is required for the
generation of T-independent antibody responses in vivo and to
promote survival of B cells stimulated through the BCR in vitro;
on the other hand, TACI-deficientmice have significantlymore
B cells (4, 5). At least inmarginal zone B cells that express TACI
highly, simultaneous engagement of Toll-like receptors andTACI
prime these cells tokillingby theFas ligand-Fas apoptoticpathway
(6). This negative function of TACI on themature B cell poolmay
explain why depletion of BAFF or of BAFF and APRIL in humans
using anti-BAFFmonoclonal antibody or a TACI-Ig decoy recep-
tor first induces an increase in memory or mature B cells (that
would be due to the release of the inhibitory function of TACI)
followedonly later byB cell depletion (thatwould be causedby the
blockade of the prosurvival function of BAFFR) (7–9).
BAFF and APRIL both crystallize as homotrimers that can
recruit three monomeric receptors per trimer (10, 11). Trimers
may not represent the optimal active unit, and a higher status of
multimerization might be required for efficient signaling (12).
BAFF has an intrinsic multimerization site distinct from the
receptor-binding site, whereas APRIL could oligomerize by
binding to proteoglycans (13, 14). Blockade of BAFF and/or
APRIL is expected to benefit autoimmune patients with excess
B cell activation and antibody production. A function-blocking
anti-BAFF antibody has shown some efficacy for the treatment
of systemic lupus and was approved in 2011 (for a review, see
Ref. 15). A TACI-Ig decoy receptor also showed encouraging
results for the treatment of the same disease (16). Inhibition of
BAFF and APRIL in mice is usually achieved with the decoy
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receptor TACI-Ig or with BCMA-Ig, whereas selective block-
ade of BAFF relies on the decoy receptor BAFFR-Ig or on 10F4,
a non-commercial hamster anti-mouse monoclonal antibody
(17–20). In this study,we describe additionalmurine antibodies
that block or activate mouse BAFF in vitro and in vivo.
Results and Discussion
A Sensitive Assay to Detect Endogenous Circulating Levels of
Mouse BAFF—A previously characterized pair of rat IgG1 anti-
mouse BAFF antibodies (5A8 and 1C9) is suitable for the detec-
tion of endogenousmouse BAFF (21, 22). Here, threemonoclo-
nal mouse IgG1 anti-mouse BAFF antibodies, Sandy-2,
Sandy-4, and Sandy-5, were purified by affinity purification on
protein A (Fig. 1A). A fourth antibody of mouse IgM isotype,
Sandy-1, did not bind to protein A or G but was partially puri-
fied by size exclusion chromatography of concentrated
hybridoma supernatants (Fig. 1A). We compared various com-
binations of sandwich ELISA and found that 5A8 as capture
antibody with Sandy-2 for revelation was the best, allowing a
more sensitive detection of mouse BAFF than the 5A8/1C9
couple (Fig. 1B). This was confirmed in a homogenous Alph-
aLISA assay in which signal is generated when donor beads
come in close contact to acceptor beads upon binding of both
antibodies to the same antigen (Fig. 1C). With the 5A8/Sandy-2
pair, endogenous BAFF in serum of WT mice or BAFF overex-
pressed in BAFF transgenic mouse serum were convincingly
detected in 0.5 l of serum with a favorable signal to noise ratio
(Fig. 1D). This indicates that the5A8andSandy-2 antibodies, both
of which are commercially available, are more sensitive than the
5A8/1C9 pair for the detection of endogenous mouse BAFF.
Anti-mouse BAFFmAbs Sandy-1, Sandy-2, and Sandy-4, but
Not Sandy-5, Prevent Binding of Mouse BAFF to All Canonical
Receptors—The extracellular domains of mouse BAFFR, TACI,
or BCMA fused to the Fc portion of an immunoglobulin, when
immobilized in an ELISA plate, all bound recombinant FLAG-
mouse BAFF, whereas the control receptor EDAR-Fc bound
FLAG-EDA1 (Fig. 2). Sandy-5 did not inhibit the binding of
mBAFF to its receptors, whereas Sandy-1, Sandy-2, and to a
lesser extent Sandy-4 specifically inhibited the binding of
FLAG-mBAFF to BAFFR, TACI, and BCMA but not of EDA1
to EDAR. As expected, the anti-EDA antibody EctoD3 abol-
ished the EDA1-EDAR interaction but did not affect mouse
BAFF (Fig. 2). Molar ratios of antibody to trimeric FLAG-
mBAFF at EC50 were about 0.5 for Sandy-1 and Sandy-2, indi-
cating an inhibition at close to stoichiometric ratio, and 1.7 for
Sandy-4 (Table 1). EctoD3 inhibited trimeric EDA with a
slightly lower ratio of 0.3 (Table 1), which is not so far away
from the previously reported value of 1.1 (23). As it is not trivial
to precisely determine protein concentrations, this difference
can probably be attributed to an overestimation of the FLAG-
EDA1 concentration or to variations in the specific activity of
different ligand preparations. In any case, this direct inhibition
assay differentiated antibodies that prevent binding of ligand to
their receptor(s) (Sandy-1, Sandy-2, Sandy-4, andEctoD3) from
those that do not (Sandy-5).
Sandy-1, Sandy-2, and to a Lesser Extent Sandy-4 Inhibit the
Agonist Activity of Mouse BAFF in Reporter Cell Assays—The
antibodies were tested in an activity assay for BAFF in which
the extracellular domains of BCMA, TACI, or BAFFR are fused
to the transmembrane and intracellular domains of the death
receptor Fas. In these cell lines, multimerization of surface-
expressed chimeric receptors by BAFF triggers the surrogate
Fas apoptotic signaling pathway and kills reporter cells (24). As
already observed in the binding assay (Fig. 2), Sandy-1 and San-
dy-2 blocked the activity of recombinant FLAG-mouse BAFF
and Fc-mouse BAFF, whereas the irrelevant antibody EctoD3
did not (Fig. 3A). The antibody to ligand ratio at EC50 was again
FIGURE1.Detectionof endogenous levelsofBAFFwithanti-mouseBAFF5A8andSandy-2mAbs.A, Coomassie Blue stainingof the indicatedmonoclonal
antibodies (10 g/lane) under reducing conditions. B, sandwich ELISA using four anti-mouse BAFF mAbs to capture mouse BAFF and two biotinylated
anti-mouse BAFFmAbs to reveal it as indicated. C, homogenous sandwich assay (AlphaLISA) for recombinantmouse BAFF using two pairs of anti-mouse BAFF
mAbs performed in the presence of BAFF/ serumdiluted 1:10.D, homogenousmouse BAFF assay (AlphaLISA) performedwith two pairs of mAbs on sera of
WT, BAFF KO, and BAFF transgenic mice diluted 1:10. Error bars represent S.E.
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close to 1 (0.4–3.9) when the assay was performed on cell lines
expressing chimeric receptors containing human TACI,
BCMA, or BAFFR but was somewhat higher (2.3–16) when
assayed in mouse BAFFR:Fas reporter cells (Fig. 3 and Table 2).
The reason why a higher ratio of inhibitory antibodies is
required to neutralize the exact same mouse BAFF prepara-
tions when assayed on mBAFFR reporter cells might be due to
a higher affinity of mBAFF for mBAFFR than for the other
receptors tested and/or to the fact that mBAFFR:Fas reporter
cells being the most sensitive to BAFF, a greater percentage of
BAFF blockade is required to achieve a given effect in these
cells. Sandy-4 inhibited FLAG-mBAFF and Fc-mBAFF activi-
ties at higher concentrations compared with Sandy-1 or San-
dy-2, especially in BAFFR:Fas reporter cells (Table 2).
Sandy-1, Sandy-2, and Sandy-4 Partially Inhibit BAFF-rich
Heteromers—Human single chain BAFF-BAFF-BAFF (BBB),
APRIL-APRIL-APRIL (AAA), and BAA and ABB heteromers
have previously been shown to signal in BCMA:Fas reporter
cells (25). Single chain mouse APRIL and BAFF homomers and
heteromers (mAAA,mBAA,mBBA, andmBBB)were tested on
BCMA:Fas reporter cells in the presence of various inhibitors.
TACI-Fc inhibited all forms of BAFF and APRIL, and
BAFFR-Fc inhibited BAFF but none of the APRIL-containing
constructs, whereas Sandy-1, Sandy-2, and Sandy-4 inhibited
BAFF but not mBAA or mAAA (Fig. 4). mBBA used at a non-
saturating concentration was only partially inhibited by San-
dy-1, Sandy-2, and Sandy-4 (Fig. 4). In summary, Sandy-1 and
Sandy-2 inhibit BAFF-rich heteromers to some extent but not
APRIL-rich heteromers.
Sandy-5 and 5A8 Activate Trimeric Mouse BAFF in a
Reporter Cell Assay, in Primary BCells in Vitro, and inVivo—In
contrast to Sandy-1, Sandy-2, and Sandy-4, Sandy-5 totally
failed to block Fc-mBAFF in a variety of reporter cell lines and
even reproducibly stimulated the activity of FLAG-mBAFF
2–5-fold (Fig. 3 and Table 2). This latter result raised the
possibility that some anti-BAFF antibodies would cross-link
FLAG-mBAFF to stimulate its activity on the reporter cell lines,
whereas Fc-mBAFF that is intrinsically cross-linkedwould ben-
efit less from this effect. To test this hypothesis, hBAFFR:Fas
reporter cells were stimulated with size-fractionated FLAG-
mBAFF trimers in the presence of various anti-mBAFF anti-
bodies. In this assay, Sandy-5 and 5A8 activated FLAG-mBAFF
about 5- and 20-fold, respectively, and 1C9 had no effect,
whereas Sandy-1, Sandy-2, and to a lesser extent Sandy-4 inhib-
ited BAFF as observed previously (Fig. 5A). This activating
effect was also observed in cultures of primarymouse B spleno-
cytes in which the prosurvival activity of BAFF was stimulated
by Sandy-5, 5A8, and to a lesser extent 1C9, whereas BAFF
antagonists (Sandy-1, Sandy-2, and Sandy-4) blocked the action
of BAFF in this assay (Fig. 5B). When 5A8 was administered
weekly at 2 mg/kg in wild type mice for 6 weeks, mature B cells
significantly increased in the spleen and in lymph nodes com-
pared with mice treated with the control antibody. Treatment
with Sandy-5 also increasedmature B cells in lymph nodes (Fig.
5, B and C). Although we did not further explore the mecha-
nismbywhich 5A8 and Sandy-5 act in vivo, we hypothesize that
the activation of the biological activity of BAFF by cross-linking
and an increased half-life of BAFF bound to antibodies both
contribute to the observed effect. Thus, we have characterized
two categories of anti-BAFF reagents: function-blocking anti-
bodies (Sandy-1, Sandy-2, and Sandy-4) that prevent binding of
BAFF to its receptors and stimulatory antibodies (Sandy-5 and
5A8) that act as cross-linkers.
A Single Administration of Sandy-2 Induces Transient B Cell
Depletion in Mice, Whereas Chronic Administration Perma-
nently Reduces B Cells—Wild type C57BL/6 mice were treated
i.p. with 2 mg/kg Sandy-2 on days 1, 7, and 14 and analyzed at
day 18 for B cell content in spleen and lymph nodes. This treat-
ment induced a significant decrease in the B/T cell ratio in both
spleen and lymph nodes when compared with an isotype-
matched control antibody (anti-EDARmAb3). B cell depletion
was at least as efficient as that obtained with the decoy receptor
FIGURE 2. Sandy-1, Sandy-2, and to a lesser extent Sandy-4 inhibit the binding of mouse BAFF to BAFFR, TACI, and BCMA. A fixed, non-saturating
concentration of FLAG-mouse BAFF (33 ng/ml) or FLAG-mEDA1 (180 ng/ml) was preincubated with serial dilutions of anti-mouse BAFF (Sandy-1, Sandy-2,
Sandy-4, and Sandy-5) or anti-EDA (EctoD3) mAbs and then applied to their cognate coated receptors-Fc. A, mBAFFR-Fc. B, mTACI-Fc. C, mBCMA-Fc. D,
hEDAR-Fc. Binding of FLAG-mouse BAFF or FLAG-mouse EDA1 to receptors was revealed via the FLAG tag, and inhibition of binding resulted in a decreased
signal. Error bars represent S.E. of triplicate measures. The experiment was performed twice with similar results.
TABLE 1
Number of antibody molecules per ligand 3-mer at EC50 in the ELISA
Data are based on data shown in Fig. 2. n.i., no inhibition.
Ligand Receptor Sandy-1 Sandy-2 Sandy-4 Sandy-5 EctoD3
FLAG-mBAFF mBAFFR-Fc 0.4 0.6 1.7 n.i. n.i.
FLAG-mBAFF mTACI-Fc 0.5 0.6 1.6 n.i. n.i.
FLAG-mBAFF mBCMA-Fc 0.4 0.5 1.7 n.i. n.i.
FLAG-mEDA1 hEDAR n.i. n.i n.i. n.i. 0.3
Monoclonal Antibodies ThatModifyMouse BAFF Function
19828 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 38•SEPTEMBER 16, 2016
 at U
niversité de Lausanne on February 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FIGURE 3. Sandy-1, Sandy-2, and to a lesser extent Sandy-4 inhibit activity of mouse BAFF. A, different reporter cell lines expressing the extracellular
domains of BAFFR, TACI, or BCMA (or EDAR as a control) fused to the transmembrane and intracellular domains of Fas (mBAFFR:Fas, hTACI:Fas, hBCMA:Fas,
hBAFFR:Fas, and hEDAR:Fas) were exposed to titrated amounts of FLAG-mouse BAFF in the presence of the indicated fixed concentrations of different
anti-mBAFF or anti-EDA (EctoD3) mAbs. After 16 h of culture, cell viability was monitored with the phenazine methosulfate/3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Blocking antibodies protect reporter cells from death. B, same as A except that Fc-mouse
BAFF (or Fc-EDA for EDAR:Fas reporter cells) was used to trigger death of reporter cells. Error bars represent S.E. of triplicate measures (except for EDAR:Fas,
monoplicates). The experiment was performed twice (once in monoplicate) with similar results.
TABLE 2
Number of antibody molecules per ligand 3-mer at EC50 in the cell-based assay
Data are based on those shown in Fig. 3. Fc ligands were considered to contain two trimers. n.i., no inhibition; n.i. (3.5); no inhibition, instead ligandwas activated 3.5-fold.
Ligand Cells Sandy-1 Sandy-2 Sandy-4 Sandy-5 EctoD3
FLAG-mBAFF hBAFFR:Fas 1.8 1 32 n.i. (3.5) n.i.
FLAG-mBAFF hBCMA:Fas 1.1 0.8 2.3 n.i. (1.8) n.i.
FLAG-mBAFF hTACI:Fas 0.7 0.5 1.3 n.i. (5.5) n.i.
FLAG-mBAFF mBAFFR:Fas 16 3.9 450 n.i. (1.9) n.i.
Fc-mBAFF hBAFFR:Fas 3.9 1.1 53 n.i. n.i.
Fc-mBAFF hBCMA:Fas 0.8 0.4 14 n.i. n.i.
Fc-mBAFF hTACI:Fas 0.4 0.4 0.8 n.i. n.i.
Fc-mBAFF mBAFFR:Fas 7.8 2.3 1600 n.i. n.i.
Fc-hEDA1 hEDAR:Fas n.i. n.i. n.i. n.i. 4.2
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TACI-Fc at 2 mg/kg (Fig. 6, A and B). In fact, a single injection
of Sandy-2 at day 1 induced at day 18 the same B cell depletion
as repeated injections. In lymph nodes, treatment with Sandy-2
generated a phenotype close to that observed in BAFF/mice
(Fig. 6,A and B). Kinetics of B cell depletion and recovery upon
treatment with anti-BAFF Sandy-2 were then studied. Upon
Sandy-2 administration, a significant decrease of circulating B
cells was detected at 1 week and was maximal at 2 weeks, and
the effect then slowly vanished over a period of 6–8 weeks (Fig.
6C). This kinetics is in line with the 10-day half-life of a mouse
IgG1 administered in mice (26). When treatment was repeated
every 2 weeks, circulating B cells were depleted to the level of
BAFF KOmice by week 4 and thereafter remained at low levels
up to the end of the experiment at 6 months (Fig. 6C).
In summary, we showed that the 5A8 rat anti-mouse BAFF
and the Sandy-5mouse anti-mouse BAFFmonoclonal antibod-
ies can potentiate the activity of recombinant trimeric mouse
BAFF in vitro and that of endogenous mouse BAFF in vivo. We
have also characterized Sandy-2, a new mouse anti-mouse
BAFFmonoclonal antibody that efficiently blocks recombinant
and endogenous BAFF in vitro and in vivo. Because Sandy-2 is a
fully mouse antibody and given its relatively long functional
half-life, it will be an interesting alternative to BAFFR-Fc, which
has been widely used so far to achieve selective inhibition of
BAFF. Sandy-2 might be especially advantageous for studies
requiring long term inhibition of BAFF with low risk of gener-
ating neutralizing antidrug responses. Finally, 5A8 and Sandy-2
forman efficient pair for sensitive quantification of endogenous
mouse BAFF.
Experimental Procedures
Animals—C57BL/6 WT and BAFF KO were as described
(12). Mice were handled according to guidelines and under the
FIGURE 4. Sandy-1, Sandy-2, and Sandy-4 partially inhibit BAFF-rich, but
norAPRIL-rich, heteromers.BCMA:Fas reporter cellswere exposed toFLAG-
mBAFF at 50 ng/ml or to unknown but lethal and non-saturating concentra-
tions of single chain mouse BAFF (mBBB), mouse APRIL (mAAA), or mouse
BAFF/APRIL heteromers (mBAA and mBBA) in the presence of the indicated
inhibitors at a concentration of 2g/ml. After 12 h of culture, cell viabilitywas
monitored with the phenazine methosulfate/3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Error
bars represent S.E. of triplicate measures. The experiment was performed
three times with similar results. One-way analysis of variance comparing
medium with inhibitors was performed: *, p  0.05; ***, p  0.001; ns, not
significant.
FIGURE 5. Sandy-5 and 5A8 stimulate trimericmouse BAFF. A, hBAFFR:Fas
reporter cells were exposed to titrated amounts of size-fractionated FLAG-
mBAFF trimers in the presence of a fixed concentration (1g/ml) of the indi-
cated anti-mBAFF or anti-EDA (EctoD3) mAbs. After 16 h of culture, cell
viabilitywasmonitoredwith thephenazinemethosulfate/3-(4,5-dimethylthi-
azol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
assay. Antibodies whose combined presence with FLAG-mouse BAFF caused
more cell death than FLAG-mouse BAFF with the control EctoD3 antibody
were considered to be activating antibodies. B, primarymouse B splenocytes
were cultured for 72 h in the presence of the indicated concentrations of
size-fractionated trimeric FLAG-mBAFF with or without inhibitors or activa-
tors at 1 g/ml. Cell viability was determined by FACS as described under
“Experimental Procedures.” Error bars represent S.E. of triplicate measures.
The experiment was performed twice (one in monoplicate) with similar
results. C and D, wild type mice were treated weekly during a 6-week period
with i.p. injections of control (EctoD1) or anti-mBAFF (Sandy-5 or 5A8) anti-
bodies at 2 mg/kg. At the end of the treatment period (day 42), lymphocytes
of the spleen and lymph nodeswere analyzed by FACS to determine ratios of
mature B cells to T cells in the spleen (C) andof B cells to T cells in lymphnodes
(D). Error bars represent S.E. One-way analysis of variance was performed: *,
p 0.05; **, p 0.01; ns, not significant.
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authorization of the Swiss Federal Food Safety and Veterinary
Office (authorization 1370.6 to P. S.). Serum from BAFF trans-
genic mice was obtained as described (27).
Antibodies, Recombinant Proteins, and Cell Lines—Anti-
mBAFF antibodies Sandy-1 (mouse IgM), Sandy-2 (AG-20B-
0063), Sandy-4, and Sandy-5 (all mouse IgG1) were provided by
Adipogen Life Sciences (Epalinges, Switzerland). Anti-mBAFF
antibodies 5A8 and 1C9 (rat IgG1) (21), anti-EDARmAb3 (26),
and anti-EDA EctoD1 and EctoD3 (23) have been described
previously. Anti-FLAG M2 antibody was from Sigma. hTACI
(aa 31–110)-hIgG1 Fc (aa 245–470, L258E,A353S,P354S) was
provided byMerck, KGaA. FLAG-mBAFF, FLAG-mEDA1, Fc-
EDA1, Fc-mBAFF, mBAFFR-Fc, mBCMA-Fc, mTACI-Fc, and
hEDAR-Fc were produced essentially as described (24, 28).
Reporter cell lines Jurkat-hBCMA:Fas clone 13 (12), Jurkat-
JOM2-hBAFFR:Fas clone 21 (25), Jurkat-JOM2-hTACI:Fas
clone 112 (29), and Jurkat-JOM2-hEDAR:Fas clone 23 (30)
were as described. Jurkat-JOM2-mBAFFR:Fas clone 20 was
generated as described (24). Table 3 summarizes sequences of
proteins expressed by plasmids used in this study.
SDS-PAGE, Coomassie Blue Staining, Western Blotting, and
Quantification of Mouse BAFF—SDS-PAGE was performed
according to standard procedures. Coomassie blue staining of
10 g of antibody per lane was performed with a semidry iD
Stain System (Eurogentech). FLAG-mBAFF purified by anti-
FLAG affinity chromatography was similarly analyzed by SDS-
PAGE and Coomassie Blue staining together with a standard
curve of 3–0.5 g of size-fractionated human His-BAFF
60-mer previously quantified by spectrophotometry assuming
a molar extinction coefficient at 280 nm of 14,565 (12). Band
intensity was quantified using ImageJ, and the concentration of
FLAG-mBAFF was determined using the standard curve of
His-hBAFF. The concentration of FLAG-mBAFF and FLAG-
mEDA1 in conditioned medium was estimated by Western
blotting against a standard curve of 10–120 ng of FLAG-
mBAFF. Proteins were revealed with anti-FLAG M2 antibody
(1g/ml) and IRDye 800CW-coupled anti-mouse antibody (65
ng/ml in PBS, 0.5% Tween 20, 1% powderedmilk) and detected
using a LI-COR Odyssey infrared fluorescence detector (LI-
COR Biosciences).
Biotinylations—1 mg of antibody in 300 l of 0.1 M sodium
borate, pH 8.8, was labeled with 100 g of EZ-Link sulfo-NHS-
LC-biotin (Pierce) in 10l of dimethyl sulfoxide for 2 h at room
temperature prior to terminating the reaction by addition of 10
l of 1 M NH4Cl and exchanging buffer to PBS.
Receptor-Ligand InteractionELISA—Purified receptors-Fc (1
g/ml in PBS) were coated into ELISA plates and incubated
with fixed concentrations of FLAG-tagged mBAFF (33 ng/ml)
or FLAG-tagged EDA1 (180 ng/ml) in supernatants of trans-
fected cells that had been preincubated with titrated amounts
of antibodies of interest. Bound FLAG-tagged ligands were
revealedwith biotinylated anti-FLAGM2 antibody (Sigma) and
horseradish-coupled streptavidin as described (24).
FIGURE 6. Sandy-2 blocks the action of endogenous BAFF in vivo. A, wild type mice were treated i.p. with the indicated inhibitors and controls at the
indicated dose and times of administration. At day 18, spleens and lymph nodes (LN) were analyzed by FACS for the presence of T (CD3) and B (CD19) cells.
Untreated BAFF/micewere analyzed in parallel. B, quantification of the experiment shown inAperformedwith twomice per group. Error bars represent S.E.
One-way analysis of variance comparing control with treatment was performed: **, p  0.01; ***, p  0.001. C, on day 1, wild type mice were treated with
anti-BAFFmAb Sandy-2. Blood lymphocytes were prepared at the indicated time points and analyzed by FACS as shown in A to determine the B to T cell ratio.
At week 2, two groups of threemice eachwere either left without further treatment (white bars) or kept under chronic Sandy-2 treatment with administration
every 2nd week (black bars). Blood of BAFF/mice was similarly analyzed for comparison. Error bars represent S.E. One-way analysis of variance comparing
initial conditionwith time points of treatment or single versus continuous treatment was performed: *, p 0.05; **, p 0.01; ***, p 0.001; ns, not significant.
The experiment was performed once.
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Sandwich ELISA—ELISA plates were coated with capture
antibodies (5A8, Sandy-1, Sandy-2, Sandy-4, or Sandy-5) at 3
g/ml in PBS, then blocked, and exposed overnight to titrated
amounts of FLAG-mBAFF. After washing, bound ligand was
revealed with 2 g/ml biotinylated anti-mBAFF antibodies
(Sandy-2 or 1C9) followed by horseradish-coupled streptavidin
and revelation with ortho-phenylenediamine as described (24).
AlphaLISA—Monoclonal antibody 5A8 (100 g) was cou-
pled for 24 h at 37 °C to 1 mg of AlphaLISA acceptor beads
(PerkinElmer Life Sciences) in 400 l of 27 mM sodium phos-
phate, pH 8, 5 mM NaBH3CN, 0.03% Tween 20. The reaction
was terminated by addition of 100l of carboxymethoxylamine
at 65mg/ml in 0.8 MNaOH for 1 h at 37 °C. Beads were washed
twice in 0.1 M Tris-HCl, pH 8, and then stored at 4 °C at a
concentration of 5 mg/ml in PBS, 0.05% Proclin-300. Assays
were performed in white 384-well plates bymixing 5l of sam-
ple, usually serum-diluted 1:10 in assay buffer (PerkinElmer
Life Sciences) with 20 l of biotinylated antibody (Sandy-2 at
0.075 g/ml or 1C9 antibody at 1.8 g/ml) and 0.5 g of 5A8
donor beads in assay buffer. After 1-h incubation at room tem-
perature, 1 g of streptavidin-coupled donor beads in 25 l of
assay buffer was added. Emission at 615 nm after excitation at
680 nm was recorded with an Enspire plate reader (Perkin-
Elmer Life Sciences).
Cytotoxic Assays with Receptor:Fas Reporter Cell Lines—
Reporter cells were incubated for 16 h with the indicated con-
centrations of ligands in the presence of the indicated inhibitors
at the indicated concentrations after which time cell viability
was measured by the phenazine methosulfate/3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium assay essentially as described (24).
Mouse B Splenocyte Survival Assay—B cells were purified
from spleens ofwild typemice using anEasySepTMmouseB cell
isolation kit (StemCell Technologies). B cells were washed with
PBS; suspended in 5 ml of PBS, 1% FCS, 2 M CFSE; incubated
for 8 min at 37 °C; washed with PBS, 2% FCS; and suspended in
complete RPMI (RPMI 1640 medium, 10% FCS, 20 M 2-mer-
captoethanol, 100 units/ml penicillin, 100 g/ml streptomy-
cin). CFSE-labeled B cells (2.5  105) were cultured in tripli-
cates in 200 l of complete RPMI in round bottomed 96-well
tissue culture plates. Cells were stimulated for 72 h at 37 °C in
medium with graded concentrations of size-fractionated
FLAG-mBAFF trimer in the presence or absence of the indi-
cated antibodies at 1 g/ml after which time cells were stained
with propidium iodide (PI; 100 ng/sample) and analyzed by
FACS (see “FACS Analyses”). The percentage of live cells was
determined as the number of live cells (CFSE, PI) divided by
the number of cells (CFSE)  100. CFSE profiles indicated
that noB cell proliferation occurred under any of the conditions
tested.
Mouse Treatments—For B cell depletion experiments, San-
dy-2, anti-EDAR mAb3 (control), or TACI-Fc were adminis-
tered i.p. to wild typemice at 2mg/kg on days 1, 7, and 14 (or on
day 1 only). Untreated BAFF KO mice were used as controls.
Mice were sacrificed at day 18 for the analysis of spleens and
lymph nodes (inguinal, axillary, and brachial). In a separate
time course experiment, two cohorts of wild type mice were
treated either once at day 1 or repeatedly every 2 weeks with
Sandy-2 at 2 mg/kg. 100 l of tail or facial vein blood was
collected on 50 l of Liquemin (500 units/ml) (DrossaPharm,
Basel, Switzerland) from the cohort with a single injection at
day11; day 3; andweeks 2, 4, 6, 10, and 28 and from the cohort
with repeated injections at day 11 and weeks 1, 4, 6, 10, and
28. Blood from BAFF KO mice was used as a control.
For B cell stimulation experiments, Sandy-5, 5A8, or EctoD3
(control) antibodies were administered i.p. to 8-week-old
C57BL/6 mice at 2 mg/kg on days 1, 7, 14, 21, 28, and 35. Mice
were sacrificed at day 42 for the analysis of spleens and lymph
nodes (inguinal, axillary, and brachial).
FACS Analyses—Secondary lymphoid organs were homoge-
nized; submitted to a red blood cell lysis step for 5min on ice in
150 mM NH4Cl, 10 mM KHCO3, 10 M Na2-EDTA; washed in
PBS, 2% FCS; and filtered on a nylon mesh. Heparinized blood
was diluted into 5 ml of PBS, cells were recovered by centrifu-
gation, and erythrocyteswere lysed in 1ml of red blood cell lysis
buffer for 5 min at room temperature. Cells were washed in
TABLE 3
Plasmids used in this study
FLAG, DYKDDDDK; HA signal, MAIIYLILLFTAVRG; Ig signal, MNFGFSLIFLVLVLKG; CamLinker, PQPQPKPQPKPEPEGS.
Plasmid Designation Protein encoded Vector
ps548 FLAG-mEDA1 HA signal-FLAG-GPGQVQLQVD-mEDA1 (aa 245–391) PCR3
ps657 FLAG-mBAFF HA signal-FLAG-GPGQVQLQVD-mBAFF (aa 127–309) PCR3
ps837 mBCMA-Fc Ig signal-DVT-mBCMA (aa 1–46)-VD-hIgG1 (aa 245–470) PCR3
ps930 hEDAR-Fc hEDAR (aa 1–183)-VD-hIgG1 (aa 245–470) PCR3
ps1111 mTACI-Fc HA signal-LE-mTACI (aa 2–78)-AAAVD-hIgG1 (aa 245–470) PCR3
ps1219 Fc-mBAFF HA signal-LD-hIgG1 (aa 245–470)-RS-CamLinker-GSLQVD-mBAFF (aa 127–309) PCR3
ps1377 pMSCS-puro Modified pMSCV-puro (Clontech) with HindIII-BglII-EcoRI-NotI-XhoI-HpaI-ApaI cloning sites ps1377
ps1199 Fc-EDA1 Signal-hIgG1 (aa 245–470)-hEDA1 (aa 238–391) PCR3
ps1938 hEDAR:Fas hEDAR (aa 1–183)-VD-hFas (aa 169–335) ps1377
ps2297 mBAFFR:Fas HA signal-LD-mBAFFR (aa 2–70)-VD-hIgG1 (aa 245–470) PCR3
ps2308 hBAFFR:Fas HA signal-LE-hBAFFR (aa 2–71)-EFGSVD-hFas (aa 169–355) ps1377
ps2309 hBCMA:Fas Ig signal-VQCEVKLVPRGS-hBCMA (aa 2–54)-VD-hFas (aa 169–335) ps1377
ps2455 hTACI:Fas HA signal-L-hTACI (aa 1–118)-VD-hFas (aa 169–335) ps1377
ps2922 mBAFFR:Fas HA signal-LE-hBAFFR (aa 2–70)-VD-hFas (aa 169–355) PCR3
ps3618 FLAG-mAAA HA signal-FLAG-GPGQVQLQVDLQ-mAPRIL (aa 95–232)-GGGGS-mAPRIL (aa 95–232)-GGGGS-
mAPRIL (aa 95–232)
PCR3
ps3637 FLAG-mBAA HA signal-FLAG-GPGQVQLQVDLQVD-mBAFF (aa 81–309)-GGGGS-mAPRIL (aa 95–232)-
GGGGS-mAPRIL (aa 95–232)
PCR3
ps3638 FLAG-mBBB HA signal-FLAG-GPGQVQLQVDLQVD-mBAFF (aa 81–309)-GGGGS-mBAFF (aa 81–309)-GGGGS-
mBAFF (aa 81–309)
PCR3
ps3640 FLAG-mBBA HA signal-FLAG-GPGQVQLQVDLQVD-mBAFF (aa 81–309)-GGGGS-mBAFF (aa 81–309)-GGGGS-
mAPRIL (aa 95–232)
PCR3
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PBS, and the lysis step was repeated. Cells were incubated with
anti-CD16/32 (Fc-block, clone 93) and stained with a mixture
of anti-CD19-phycoerythrin.Cy7 (clone eBio1D3; 1:100); anti-
CD3-allophycocyanin (clone 17A2; 1:100) (all from eBiosci-
ences); and in some cases biotinylated anti-CD93 (clone
mAb493; a kind gift from Antonius Rolink, University of Basel,
Switzerland) followed by streptavidin-phycoerythrin.Cy5.5 for
20 min on ice before analysis with an Accuri C6 or FACSCanto
flow cytometer (BD Biosciences). Data were analyzed with the
FlowJo software (TreeStar, Ashland, OR).
Statistics—For the determination of EC50 values, normalized
data expressed as a function of the logarithm of concentration
were analyzed using the “log(agonist) versus normalized
response, variable slope” function of Prism (GraphPad Soft-
ware). One-way analysis of variance with Bonferroni’s multiple
comparison tests was used to compare selected groups using
Prism.
Author Contributions—O. D., J.-E. G., and P. S. conceived experi-
ments. C. K.-Q. (Figs. 1, 2, 3, 5, and 6), S. S.-M. (Figs. 1, 5, and 6),
L. W. (Figs. 1, 2, 3, and 4),M. V. (Figs. 1, 2, and 5), A. T. (Figs. 5 and 6),
C. R. S. (Fig. 1), and P. S. (Figs. 1, 3, and 4) performed experiments.
T. S. Z. (Fig. 6), J. G. (Fig. 1), F. M. (Figs. 1 and 5), O. D. (Figs. 1 and 6),
and H. H. (Figs. 4 and 6) contributed experimental ideas and key
reagents to perform them. P. S. wrote the paper. C. R. S., M. V., and
F. M. edited the manuscript. All authors reviewed the results and
approved the final version of the manuscript.
Acknowledgments—We are grateful to Susan Kalled (Biogen, Boston,
MA) for providing BAFF/ mice and to William Figgett (Monash
University, Melbourne, Australia) for independent confirmation of
the inhibitory activity of Sandy-2.
References
1. Mackay, F., and Schneider, P. (2009) Cracking the BAFF code. Nat. Rev.
Immunol. 9, 491–502
2. Gras, M. P., Laâbi, Y., Linares-Cruz, G., Blondel, M. O., Rigaut, J. P.,
Brouet, J. C., Leca, G., Haguenauer-Tsapis, R., and Tsapis, A. (1995)
BCMAp: an integral membrane protein in the Golgi apparatus of human
mature B lymphocytes. Int. Immunol. 7, 1093–1106
3. O’Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K.,
Ahonen, C., Lin, L. L., Mantchev, G. T., Bram, R. J., andNoelle, R. J. (2004)
BCMA is essential for the survival of long-lived bonemarrow plasma cells.
J. Exp. Med. 199, 91–98
4. von Bülow, G., van Deursen, J. M., and Bram, R. J. (2001) Regulation of the
T-independent humoral response by TACI. Immunity 14, 573–582
5. Yan, M., Wang, H., Chan, B., Roose-Girma, M., Erickson, S., Baker, T.,
Tumas, D., Grewal, I. S., and Dixit, V. M. (2001) Activation and accumu-
lation of B cells in TACI-deficient mice. Nat. Immunol. 2, 638–643
6. Figgett,W.A., Fairfax, K., Vincent, F. B., Le Page,M.A., Katik, I., Deliyanti,
D., Quah, P. S., Verma, P., Grumont, R., Gerondakis, S., Hertzog, P.,
O’Reilly, L. A., Strasser, A., and Mackay, F. (2013) The TACI receptor
regulates T-cell-independent marginal zone B cell responses through in-
nate activation-induced cell death. Immunity 39, 573–583
7. Stohl,W., Hiepe, F., Latinis, K.M., Thomas,M., Scheinberg,M. A., Clarke,
A., Aranow, C., Wellborne, F. R., Abud-Mendoza, C., Hough, D. R.,
Pineda, L., Migone, T. S., Zhong, Z. J., Freimuth,W.W., Chatham,W.W.,
BLISS-52 Study Group, and BLISS-76 Study Group (2012) Belimumab
reduces autoantibodies, normalizes low complement levels, and reduces
select B cell populations in patients with systemic lupus erythematosus.
Arthritis Rheum. 64, 2328–2337
8. Tak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I., Dimic, A., Mircetic,
V., Rischmueller, M., Nasonov, E., Shmidt, E., Emery, P., and Munafo, A.
(2008) Atacicept in patients with rheumatoid arthritis: results of a multi-
center, phase Ib, double-blind, placebo-controlled, dose-escalating, sin-
gle- and repeated-dose study. Arthritis Rheum. 58, 61–72
9. Wallace, D. J., Stohl,W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T.,
Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., Fernandez,
V., Chevrier, M. R., Zhong, Z. J., and Freimuth, W. W. (2009) A phase II,
randomized, double-blind, placebo-controlled, dose-ranging study of be-
limumab in patients with active systemic lupus erythematosus. Arthritis
Rheum. 61, 1168–1178
10. Hymowitz, S. G., Patel, D. R.,Wallweber, H. J., Runyon, S., Yan,M., Yin, J.,
Shriver, S. K., Gordon, N. C., Pan, B., Skelton, N. J., Kelley, R. F., and
Starovasnik, M. A. (2005) Structures of APRIL-receptor complexes: like
BCMA, TACI employs only a single cysteine-rich domain for high affinity
ligand binding. J. Biol. Chem. 280, 7218–7227
11. Liu, Y., Hong, X., Kappler, J., Jiang, L., Zhang, R., Xu, L., Pan, C. H.,Martin,
W. E., Murphy, R. C., Shu, H. B., Dai, S., and Zhang, G. (2003) Ligand-
receptor binding revealed by the TNF family member TALL-1. Nature
423, 49–56
12. Bossen, C., Cachero, T. G., Tardivel, A., Ingold, K., Willen, L., Dobles, M.,
Scott, M. L., Maquelin, A., Belnoue, E., Siegrist, C. A., Chevrier, S., Acha-
Orbea, H., Leung, H., Mackay, F., Tschopp, J., and Schneider, P. (2008)
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL
to support survival of activated B cells and plasmablasts. Blood 111,
1004–1012
13. Ingold, K., Zumsteg, A., Tardivel, A., Huard, B., Steiner, Q. G., Cachero,
T. G., Qiang, F., Gorelik, L., Kalled, S. L., Acha-Orbea, H., Rennert, P. D.,
Tschopp, J., and Schneider, P. (2005) Identification of proteoglycans as the
APRIL-specific binding partners. J. Exp. Med. 201, 1375–1383
14. Liu, Y., Xu, L., Opalka, N., Kappler, J., Shu, H. B., and Zhang, G. (2002)
Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family
ligands. Cell 108, 383–394
15. Stohl, W. (2014) Therapeutic targeting of the BAFF/APRIL axis in sys-
temic lupus erythematosus. Expert Opin. Ther. Targets 18, 473–489
16. Isenberg, D., Gordon, C., Licu, D., Copt, S., Rossi, C. P., and Wofsy, D.
(2015) Efficacy and safety of atacicept for prevention of flares in patients
with moderate-to-severe systemic lupus erythematosus (SLE): 52-week
data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006–2015
17. Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K.,
Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., Moore, M., Littau,
A., Grossman, A., Haugen, H., Foley, K., Blumberg, H., Harrison, K.,
Kindsvogel, W., and Clegg, C. H. (2000) TACI and BCMA are receptors
for a TNF homologue implicated in B-cell autoimmune disease. Nature
404, 995–999
18. Pelletier,M., Thompson, J. S., Qian, F., Bixler, S. A., Gong, D., Cachero, T.,
Gilbride, K., Day, E., Zafari, M., Benjamin, C., Gorelik, L., Whitty, A.,
Kalled, S. L., Ambrose, C., and Hsu, Y. M. (2003) Comparison of soluble
decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF.
J. Biol. Chem. 278, 33127–33133
19. Ramanujam,M., Bethunaickan, R., Huang,W., Tao,H.,Madaio,M. P., and
Davidson, A. (2010) Selective blockade of BAFF for the prevention and
treatment of systemic lupus erythematosus nephritis in NZM2410 mice.
Arthritis Rheum. 62, 1457–1468
20. Scholz, J. L., Crowley, J. E., Tomayko, M. M., Steinel, N., O’Neill, P. J.,
Quinn, W. J., 3rd, Goenka, R., Miller, J. P., Cho, Y. H., Long, V., Ward, C.,
Migone, T. S., Shlomchik, M. J., and Cancro, M. P. (2008) BLyS inhibition
eliminates primary B cells but leaves natural and acquired humoral immu-
nity intact. Proc. Natl. Acad. Sci. U.S.A. 105, 15517–15522
21. Batten,M., Fletcher, C., Ng, L. G., Groom, J.,Wheway, J., Laâbi, Y., Xin, X.,
Schneider, P., Tschopp, J., Mackay, C. R., and Mackay, F. (2004) TNF
deficiency fails to protect BAFF transgenic mice against autoimmunity
and reveals a predisposition to B cell lymphoma. J. Immunol. 172,
812–822
22. Bossen, C., Tardivel, A., Willen, L., Fletcher, C. A., Perroud, M., Beer-
mann, F., Rolink, A. G., Scott, M. L., Mackay, F., and Schneider, P. (2011)
Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and
antibody responses. Eur. J. Immunol. 41, 787–797
23. Kowalczyk-Quintas, C., and Schneider, P. (2014) Ectodysplasin A
Monoclonal Antibodies ThatModifyMouse BAFF Function
SEPTEMBER 16, 2016•VOLUME 291•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 19833
 at U
niversité de Lausanne on February 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(EDA)—EDA receptor signalling and its pharmacological modulation.
Cytokine Growth Factor Rev. 25, 195–203
24. Schneider, P.,Willen, L., and Smulski, C. R. (2014)Tools and techniques to
study ligand-receptor interactions and receptor activation by TNF super-
family members.Methods Enzymol. 545, 103–125
25. Schuepbach-Mallepell, S., Das, D., Willen, L., Vigolo, M., Tardivel, A.,
Lebon, L., Kowalczyk-Quintas, C., Nys, J., Smulski, C., Zheng, T. S., Mas-
kos, K., Lammens, A., Jiang, X., Hess, H., Tan, S.-L., and Schneider, P.
(2015) Stoichiometry of heteromeric BAFF and APRIL cytokines dictates
their receptor-binding and signaling properties. J. Biol. Chem. 290,
16330–16342
26. Kowalczyk, C., Dunkel, N., Willen, L., Casal, M. L., Mauldin, E. A., Gaide,
O., Tardivel, A., Badic, G., Etter, A. L., Favre,M., Jefferson, D.M., Headon,
D. J., Demotz, S., and Schneider, P. (2011) Molecular and therapeutic
characterization of anti-ectodysplasin A receptor (EDAR) agonist mono-
clonal antibodies. J. Biol. Chem. 286, 30769–30779
27. McCarthy, D. D., Kujawa, J., Wilson, C., Papandile, A., Poreci, U., Porfilio,
E. A., Ward, L., Lawson, M. A., Macpherson, A. J., McCoy, K. D., Pei, Y.,
Novak, L., Lee, J. Y., Julian, B. A., Novak, J., Ranger, A., Gommerman, J. L.,
and Browning, J. L. (2011)Mice overexpressing BAFF develop a commen-
sal flora-dependent, IgA-associated nephropathy. J. Clin. Investig. 121,
3991–4002
28. Schneider, P. (2000) Production of recombinantTRAIL andTRAIL recep-
tor:Fc chimeric proteins.Methods Enzymol. 322, 325–345
29. Kimberley, F. C., van der Sloot, A. M., Guadagnoli, M., Cameron, K.,
Schneider, P., Marquart, J. A., Versloot, M., Serrano, L., andMedema, J. P.
(2012) The design and characterization of receptor-selective APRIL vari-
ants. J. Biol. Chem. 287, 37434–37446
30. Swee, L. K., Ingold-Salamin, K., Tardivel, A., Willen, L., Gaide, O., Favre,
M., Demotz, S.,Mikkola,M., and Schneider, P. (2009) Biological activity of
ectodysplasin A is conditioned by its collagen and heparan sulfate pro-
teoglycan-binding domains. J. Biol. Chem. 284, 27567–27576
Monoclonal Antibodies ThatModifyMouse BAFF Function
19834 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 38•SEPTEMBER 16, 2016
 at U
niversité de Lausanne on February 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Schneider
Henry Hess, Jacques-Eric Gottenberg, Fabienne Mackay, Olivier Donzé and Pascal
Willen, Aubry Tardivel, Cristian R. Smulski, Timothy S. Zheng, Jennifer Gommerman, 
Christine Kowalczyk-Quintas, Sonia Schuepbach-Mallepell, Michele Vigolo, Laure
Cell Hyperplasia
Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B 
Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor
doi: 10.1074/jbc.M116.725929 originally published online July 22, 2016
2016, 291:19826-19834.J. Biol. Chem. 
  
 10.1074/jbc.M116.725929Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/291/38/19826.full.html#ref-list-1
This article cites 30 references, 13 of which can be accessed free at
 at U
niversité de Lausanne on February 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
